Clinical trial
Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)
NCT00116298 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00116298 |
|---|---|
| Title | Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) |
| Official title | A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, AIDS |
| Intervention type | Drug |
| Interventions | stavudine, efavirenz, lamivudine |
| Enrollment | 900 |
| Start date | Jan 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jun 29, 2005 |
| Last update posted | Apr 25, 2011 |
| Countries | Argentina, Belgium, Brazil, Canada, France, Israel, Italy, Mexico, Portugal, Puerto Rico, Russia, Singapore and 4 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: